Incyte beats Q2 revenue estimates on strong product demand

Overview

• U.S. biopharma firm's Q2 total revenue rose 38% yr/yr, beating analyst expectations

• Adjusted EPS for Q2 beat analyst expectations

• Company raised 2026 full-year net sales guidance after CMS settlement boosted Opzelura sales

Outlook

• Incyte raises 2026 total net sales guidance to $5.13-$5.26 bln

• Company raises 2026 Opzelura net sales guidance to $1.05-$1.1 bln

• Incyte raises 2026 Hematology and Oncology net sales guidance to $860-$890 mln

Result Drivers

• PRODUCT DEMAND - Increased demand for Jakafi, Opzelura (excluding the one-time benefit), and Hematology/Oncology products such as Niktimvo, Monjuvi/Minjuvi, and Zynyz contributed to underlying sales growth

• HIGHER OPERATING EXPENSES - Operating expenses rose due to increased R&D investment in late-stage assets and higher SG&A spending on marketing and pre-launch activities

Company press release: ID:nBw6PBtxKa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 15 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Incyte Corp is $112.00, about 5.8% below its July 27 closing price of $118.87

• The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 12 three months ago

Reuters Recommended Reads

• July 27 - AstraZeneca Q2 revenue rises 6% on demand for its cancer therapies

• July 27 - Argenx to buy Forte Biosciences for about $2.2 billion

• July 27 - Universal Health Services cuts 2026 forecast on Medicaid reimbursement uncertainty

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)